MYCOF / Mydecine Innovations closes 'best efforts' overnight marketed offering for aggregate gross proceeds of $2,814,199.50

Mydecine Innovations Group Inc (OTC:MYCOF, NEO:MYCO) said it has closed its previously announced 'best efforts' overnight marketed offering of units f more_horizontal

Mydecine Innovations Group Inc (OTC:MYCOF, NEO:MYCO) has announced the size of its previously announced overnight public offering, saying it will issu more_horizontal

Mydecine Innovations Group Inc (OTC:MYCOF, NEO:MYCO) ended 2021 with C$1.5 million in cash and decribed the just-ended financial year as one in which more_horizontal

Mydecine Innovations Group Inc (OTC:MYCOF, NEO:MYCO). said it has received conditional approval from the Institutional Review Board (IRB) for its mult more_horizontal

Learn more about Mydecine's clinical trials and drug development strategy by scheduling a meeting with management Learn more about Mydecine's clinical more_horizontal

Learn more about Mydecine's clinical trials and drug development strategy by scheduling a meeting with management Learn more about Mydecine's clinical more_horizontal

Learn more about Mydecine's clinical trials and drug development strategy by scheduling a meeting with management Learn more about Mydecine's clinical more_horizontal

Mydecine Innovations Group Inc (OTC:MYCOF, NEO:MYCO) has announced the inclusion of a novel molecule with potentially heart-safe microdose enabling pr more_horizontal